Methods of decreasing the effects of oxidative stress using N-acetylcysteine
    1.
    发明授权
    Methods of decreasing the effects of oxidative stress using N-acetylcysteine 有权
    使用N-乙酰半胱氨酸降低氧化应激作用的方法

    公开(公告)号:US06627659B1

    公开(公告)日:2003-09-30

    申请号:US09926363

    申请日:2001-10-22

    IPC分类号: A61K31195

    CPC分类号: A61K31/198

    摘要: The present invention relates to methods of decreasing the effects of oxidative stress in patients undergoing hemodialysis by intravenously administering N-acetylcysteine or a pharmaceutically acceptable salt thereof to the patient.

    摘要翻译: 本发明涉及通过向患者静脉内施用N-乙酰半胱氨酸或其药学上可接受的盐来降低进行血液透析的患者的氧化应激作用的方法。

    Process for the preparation of heteroaryl-zinc halides
    2.
    发明授权
    Process for the preparation of heteroaryl-zinc halides 失效
    制备杂芳基 - 卤化锌的方法

    公开(公告)号:US06211380B1

    公开(公告)日:2001-04-03

    申请号:US09341297

    申请日:1999-07-08

    IPC分类号: C07F306

    CPC分类号: C07D277/30 C07F3/06

    摘要: A process for the preparation of heteroaryl-zinc halides of the formula (II): Het—Zn—X, wherein Het is an optionally substituted 5 or 6 membered aromatic heterocyclic group with one or two heteroatoms selected among nitrogen, oxygen or sulphur; X is a chlorine, bromine or iodine atom; comprising metallation reaction of heteroarylhalide with metallic zinc optionally activated by washing with acids, is described. Compounds of the formula (II) are intermediates useful in the synthesis for the preparation of compounds endowed with pharmacological activity.

    摘要翻译: 制备式(II)的杂芳基 - 卤化锌的方法:Het-Zn-X,其中Het是具有一个或两个选自氮,氧或硫的杂原子的任选取代的5或6元芳族杂环基; X是氯,溴或碘原子; 包括杂芳基卤化物与任选通过用酸洗涤而活化的金属锌的金属化反应。 式(II)的化合物是用于合成制备具有药理学活性的化合物的中间体。

    Phosphonyldipeptides useful in the treatment of cardiovascular diseases
    5.
    发明授权
    Phosphonyldipeptides useful in the treatment of cardiovascular diseases 失效
    可用于治疗心血管疾病的膦酰二肽

    公开(公告)号:US5760285A

    公开(公告)日:1998-06-02

    申请号:US702701

    申请日:1996-09-13

    CPC分类号: C07K5/06191 A61K38/00

    摘要: Compounds of formula (II) ##STR1## wherein R is a biphenyl group optionally substituted by one or more substituents, the same or different, selected among halogen atoms, hydroxy groups, alkoxy, alkyl or thioalkyl groups having from 1 to 6 carbon atoms in the alkyl moiety, carboxylic groups, nitro groups, amino, mono- or di-alkylamino groups having from 1 to 6 carbon atoms in the alkyl moiety; R.sub.1 is a hydrogen atom or a straight or branched C.sub.1 -C.sub.4 allyl; R.sub.2 is a straight or branched C.sub.1 -C.sub.6 alkyl or an arylalkyl having from 1 to 6 carbon atoms in the alkyl moiety wherein the aryl is a phenyl, a naphthyl or a 5 or 6 membered aromatic heterocycle with one or two heteroatoms selected among nitrogen, oxygen and sulphur, optionally substituted as above indicated for the R substituent; R.sub.3 is a straight or branched C.sub.1 -C.sub.6 alkyl, optionally containing one or more fluorine atoms, or an arylalkyl having from 1 to 6 carbon atoms in the alkyl moiety; the carbon atoms marked with an asterisk are asymmetric carbon atoms; and their pharmaceutically acceptable salts, are described. The compounds of formula (II) are useful in the treatment of cardiovascular diseases.

    摘要翻译: PCT No.PCT / EP95 / 01322 Sec。 371日期1996年9月13日 102(e)1996年9月13日PCT PCT 1995年4月11日PCT公布。 WO95 / 28417 PCT出版物 日期:1995年10月26日化学式(II)其中R是任选被一个或多个选自卤素原子,羟基,烷氧基,烷基或硫代烷基中的一个或多个相同或不同的取代基取代的联苯基 在烷基部分具有1至6个碳原子,在烷基部分具有1至6个碳原子的羧基,硝基,氨基,一或二烷基氨基; R1是氢原子或直链或支链C1-C4烯丙基; R2是直链或支链的C 1 -C 6烷基或在烷基部分具有1至6个碳原子的芳基烷基,其中芳基是苯基,萘基或具有一个或两个选自氮, 氧和硫,任选地被如上述R取代基所取代; R3是任选地含有一个或多个氟原子的直链或支链C 1 -C 6烷基或在烷基部分具有1至6个碳原子的芳基烷基; 标有星号的碳原子是不对称碳原子; 及其药学上可接受的盐。 式(II)的化合物可用于治疗心血管疾病。